We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Risk factors for early adverse outcomes after bovine jugular vein conduit implantation: influence of oversized conduit on the outcomes.
- Authors
Kim, Dong-Hee; Kwon, Young Kern; Choi, Eun Seok; Kwon, Bo Sang; Park, Chun Soo; Yun, Tae-Jin
- Abstract
Open in new tab Download slide OBJECTIVES We investigated potential risk factors for early failure of bovine jugular vein conduit (Contegra®) implantation for right ventricular outflow tract (RVOT) reconstruction. METHODS A single-centre retrospective review of 115 consecutive patients (54 males) who underwent RVOT reconstruction with Contegra between 2016 and 2019 was performed. Overall survival, explantation-free survival and freedom from significant RVOT lesions (valve regurgitation ≥ moderate or flow velocity ≥3.5 m/s) were investigated. RESULTS Median age, body weight and Contegra diameter were 10.3 months [interquartile range (IQR) 5.7–26.9 months], 7.8 kg (IQR 6.3–12.4 kg) and 14 mm (IQR 12–16 mm), respectively. During the median follow-up duration of 25.1 months, there were 7 deaths, 34 significant RVOT lesions, 10 endocarditis episodes and 15 explantations. Overall survival and explantation-free survival at 3 years were 94.8% and 78.4%, respectively. Significant RVOT lesions (n = 34) comprised 20 stenoses, 8 regurgitations and 6 combined lesions. Freedom from significant RVOT lesions at 3 years was 62.6%. Cox regression identified higher indexed Contegra size (Contegra diameter/body weight, mm/kg) as the only risk factor for decreased time to explantation or death (hazard ratio 2.32, P < 0.001) and time to significant RVOT lesions development (hazard ratio 2.75, P < 0.001). The cut-off value of indexed Contegra size for significant RVOT lesions at 12 months was 1.905 mm/kg (sensitivity, 0.75; specificity, 0.78; area under the curve, 0.82). CONCLUSIONS Outcomes of RVOT reconstruction using Contegra were acceptable. However, oversized Contegra should be avoided when possible. IRB APPROVAL DATE 26 October 2020. IRB REGISTRATION NUMBER S2020-2505-0001
- Publication
Interactive Cardiovascular & Thoracic Surgery, 2022, Vol 35, Issue 4, p1
- ISSN
1569-9293
- Publication type
Article
- DOI
10.1093/icvts/ivac197